Donnerstag, 08. Dezember 2016


  • Pressemitteilung BoxID 150695

Nutra Pharma's Distributor, XenaCare Holdings Announces Changes to Cobroxin Advertising Campaign and Signing of Professional Athletic Sponsorship

(lifePR) (Delray Beach, Fla., ) Due to Unforeseen Timing Circumstances with NCAA Gameday Program Publisher, Professional Sports Publications, XenaCare Will Be Replacing Its Cobroxin Advertisements Scheduled to Appear in the National Collegiate Athletic Association (NCAA) Programs with Advertisements in Major League Baseball (MLB) Yearbooks. in Addition, the Company Has Announced the Signing of a Professional Athletic Sponsorship with Volleyball Player, Megan Wallin.

XenaCare Holdings, Inc. (OTCBB:XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it will be replacing advertisements scheduled to appear in the National Collegiate Athletic Association (NCAA) March Madness Tournament program and Final Four Game program with advertisements in Major League Baseball (MLB) yearbooks. The change in advertising occurred due to unforeseen timing circumstances with Professional Sports Publications, the publisher of the NCAA gameday programs.

As a replacement to its National Collegiate Athletic Association (NCAA) advertising campaign, XenaCare will be publishing Cobroxin advertisements in upcoming Major League Baseball (MLB) yearbooks. The advertisements are scheduled to run in the yearbooks of 6 major league cities, including the New York Mets, the Los Angeles Dodgers and the Chicago Cubs, and represents approximately seven times the viewership of that of the NCAA advertising campaign.

In addition to its marketing campaign with Major League Baseball, XenaCare is proud to announce an athletic sponsorship with Megan Wallin, a professional beach volleyball player on the AVP Tour. Megan, a Florida native, has proven to be a strong force on the sand and in the world of business and has had six professional wins and 10 finals appearances in 2009; she also competed against the two-time gold medalists from the 2004 Athens Olympics and 2008 Beijing Olympics. Megan is also the founder and author of SpikeKey.com Magazine.

"We are pleased to welcome Megan Wallin to the Cobroxin team," commented Frank Rizzo, President and CEO of XenaCare Holdings. "We look forward to working closely with Megan as we continue to expand our national advertising campaign and feature her in our upcoming print advertisements," he concluded.

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. Cobroxin is currently available as an Advanced Oral Spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as an Advanced Topical Gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additional benefits to Cobroxin include:

- All Natural
- Non-Addictive
- Non-Narcotic
- Non-Opiate
- Long Lasting

XenaCare Holdings was granted a license by Nutra Pharma Corporation (OTCBB: NPHC), the biotechnology company that developed and currently manufactures Cobroxin, to market and distribute Cobroxin within the United States.

www.nutrapharma.com
www.Cobroxin.com

Undiscovered Equities

Nutra Pharma Corporation (the "Company") operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena that it investigates about possibly acquiring or establish strategic partnerships with.

http://www.nutrapharma.com
http://www.Cobroxin.com

Diese Pressemitteilungen könnten Sie auch interessieren

Ralf Schnelle neuer Geschäftsführer der TP Industrial Deutschland GmbH

, Medien & Kommunikation, Pirelli Deutschland GmbH

Ralf Schnelle (47) übernahm zum 01. Dezember 2016 die Geschäftsführung der TP Industrial Deutschland GmbH, Breuberg. Er folgt in dieser Funktion...

TÜV SÜD: Ein Siegel fürs Zukunftspotenzial

, Medien & Kommunikation, TÜV SÜD AG

Anlässlich ihres 150-jährigen Jubiläums schreibt die TÜV SÜD AG einen Innovationspreis für kleine und mittelständische Unternehmen (KMU) aus,...

Zum 100. Geburtstag von KIRK DOUGLAS: Auftakt der neuen DVD-Reihe „Unvergessliche Filmstars“!

, Medien & Kommunikation, SchröderMedia

Zum bevorstehenden ehrenvollen 100. Geburtstag von KIRK DOUGLAS am 9.Dezember 2016 startet die neue DVD-Reihe „Unvergessliche Filmstars“ mit...

Disclaimer